Business Description
CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, focused on developing cancer treatments that work more precisely within the tumor environment. Its core technology, the PROBODY platform, is designed to activate cancer-fighting drugs only at the tumor site, reducing harm to healthy tissue and improving patient safety. The company has several drug candidates in development, including treatments that engage the immune system to attack cancer cells, and maintains partnerships with major pharmaceutical companies such as Amgen, Bristol Myers Squibb, and Merck. Founded in 2008, CytomX continues to build a broad pipeline of next-generation cancer therapies across multiple treatment approaches.
